{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:46:22Z","timestamp":1792788382281,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kafr El Shiekh University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pompe disease is a rare genetic disorder caused by a deficiency of the enzyme acid alpha-glucosidase. This condition leads to muscle weakness, respiratory problems, and heart abnormalities in affected individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The aim of the study is to share our experience through cross sectional study of patients with infantile-onset Pompe disease (IOPD) with different genetic variations, resulting in diverse clinical presentations. We evaluated their phenotype, genotype, radiological and laboratory findings including their cross-reactive immunologic material (CRIM) status. Infantile Pompe disease was diagnosed by measurement of the activity of the enzyme alpha-glucosidase. The diagnosis was confirmed by molecular genetic testing using PCR amplification and sequencing of the acid alpha-glucosidase (\n                      <jats:italic>GAA<\/jats:italic>\n                      ) gene. Routine two-D echocardiography, and multi-parametric ECG-gated cardiac magnetic resonance imaging (CMR) were done to patients six months after starting enzyme replacement therapy (ERT).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The results of our study revealed different genetic mutations among our patients, different CRIM status and also CMR abnormalities. CMR imaging revealed abnormalities in all cases that underwent the procedure, including myocardial and vascular changes, with feature tracking indicating issues across all parameters and LGE suggesting fibrosis. The patient with a positive immune response had the most severe cardiac abnormalities, despite improvements in muscle weakness and motor skills from ERT. This underscores that delayed diagnosis and ERT can lead to irreversible heart damage from autophagy buildup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pompe disease has various clinical presentations and results in significant CMR findings, which can be attributed to different genetic mutations. Early initiation of enzyme replacement therapy in infantile-onset Pompe disease is important to maximize its benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13052-025-01837-8","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T05:46:05Z","timestamp":1737611165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical manifestations in Egyptian Pompe disease patients: Molecular variability and enzyme replacement therapy\u00a0(ERT) outcomes"],"prefix":"10.1186","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6098-9752","authenticated-orcid":false,"given":"Mohamed Abdelghafar","family":"Hussein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"ElTaher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranim","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donia","family":"Sobh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Al-Haggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"4","key":"1837_CR1","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","volume":"15","author":"L Kohler","year":"2018","unstructured":"Kohler L, Puertollano R, Raben N. Pompe disease: from Basic Science to Therapy. Neurotherapeutics. 2018;15(4):928\u201342.","journal-title":"Neurotherapeutics"},{"issue":"3","key":"1837_CR2","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","volume":"268","author":"HA Wisselaar","year":"1993","unstructured":"Wisselaar HA, et al. Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem. 1993;268(3):2223\u201331.","journal-title":"J Biol Chem"},{"issue":"3","key":"1837_CR3","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ncl.2014.04.010","volume":"32","author":"M Dasouki","year":"2014","unstructured":"Dasouki M, et al. Pompe disease: literature review and case series. Neurol Clin. 2014;32(3):751\u201376. ix.","journal-title":"Neurol Clin"},{"issue":"1","key":"1837_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13023-018-0771-0","volume":"13","author":"R Parini","year":"2018","unstructured":"Parini R, et al. Long term clinical history of an Italian cohort of infantile onset pompe disease treated with enzyme replacement therapy. Orphanet J Rare Dis. 2018;13(1):32.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1837_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgme.2011.02.004","volume":"103","author":"BJ Byrne","year":"2011","unstructured":"Byrne BJ, et al. Pompe disease: design, methodology, and early findings from the Pompe Registry. Mol Genet Metab. 2011;103(1):1\u201311.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"1837_CR6","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1007\/s00415-015-7664-0","volume":"262","author":"F Montagnese","year":"2015","unstructured":"Montagnese F, et al. Clinical and molecular aspects of 30 patients with late-onset pompe disease (LOPD): unusual features and response to treatment. J Neurol. 2015;262(4):968\u201378.","journal-title":"J Neurol"},{"issue":"4","key":"1837_CR7","first-page":"271","volume":"117","author":"LB Bay","year":"2019","unstructured":"Bay LB, et al. Infantile-onset pompe disease: diagnosis and management. Arch Argent Pediatr. 2019;117(4):271\u20138.","journal-title":"Arch Argent Pediatr"},{"issue":"13","key":"1837_CR8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.21037\/atm.2019.07.24","volume":"7","author":"A Toscano","year":"2019","unstructured":"Toscano A, Rodolico C, Musumeci O. Multisystem late onset pompe disease (LOPD): an update on clinical aspects. Ann Transl Med. 2019;7(13):284.","journal-title":"Ann Transl Med"},{"key":"1837_CR9","unstructured":"Disease AW et al. G.o.M.o.P.,., Pompe disease diagnosis and management guideline. Genet Med, 2006. 8(5): pp. 267\u2009\u2013\u200988."},{"key":"1837_CR10","first-page":"CD011539","volume":"11","author":"M Chen","year":"2017","unstructured":"Chen M, Zhang L, Quan S. Enzyme replacement therapy for infantile-onset pompe disease. Cochrane Database Syst Rev. 2017;11:CD011539.","journal-title":"Cochrane Database Syst Rev"},{"key":"1837_CR11","first-page":"250","volume":"94","author":"AG Engel","year":"1969","unstructured":"Engel AG. Acid maltase deficiency of adult life. Trans Am Neurol Assoc. 1969;94:250\u20132.","journal-title":"Trans Am Neurol Assoc"},{"issue":"1\u20132","key":"1837_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cccn.2004.04.009","volume":"347","author":"NA Chamoles","year":"2004","unstructured":"Chamoles NA, et al. Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. Clin Chim Acta. 2004;347(1\u20132):97\u2013102.","journal-title":"Clin Chim Acta"},{"issue":"10","key":"1837_CR13","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/humu.23059","volume":"37","author":"WS Oetting","year":"2016","unstructured":"Oetting WS, et al. Clinical interpretation of variants from Next-Generation sequencing: the 2016 scientific meeting of the Human Genome Variation Society. Hum Mutat. 2016;37(10):1110\u20133.","journal-title":"Hum Mutat"},{"issue":"1","key":"1837_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, et al. Cross-reactive immunologic material status affects treatment outcomes in pompe disease infants. Mol Genet Metab. 2010;99(1):26\u201333.","journal-title":"Mol Genet Metab"},{"issue":"8","key":"1837_CR15","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.echo.2008.02.006","volume":"21","author":"MD Pettersen","year":"2008","unstructured":"Pettersen MD, et al. Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr. 2008;21(8):922\u201334.","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"1837_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12933-018-0681-4","volume":"17","author":"PP Swoboda","year":"2018","unstructured":"Swoboda PP, et al. Cardiovascular magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control and clinical outcomes. Cardiovasc Diabetol. 2018;17(1):35.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1837_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1532-429X-11-19","volume":"11","author":"EV Buechel","year":"2009","unstructured":"Buechel EV, et al. Normal right- and left ventricular volumes and myocardial mass in children measured by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2009;11(1):19.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"1837_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1532-429X-14-77","volume":"14","author":"I Voges","year":"2012","unstructured":"Voges I, et al. Normal values of aortic dimensions, distensibility, and pulse wave velocity in children and young adults: a cross-sectional study. J Cardiovasc Magn Reson. 2012;14(1):77.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"10","key":"1837_CR19","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1002\/ajmg.a.36110","volume":"161A","author":"PS Kishnani","year":"2013","unstructured":"Kishnani PS, et al. Timing of diagnosis of patients with pompe disease: data from the pompe registry. Am J Med Genet A. 2013;161A(10):2431\u201343.","journal-title":"Am J Med Genet A"},{"issue":"3","key":"1837_CR20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1021\/acs.bioconjchem.6b00696","volume":"28","author":"TJ Deming","year":"2017","unstructured":"Deming TJ. Functional modification of Thioether groups in peptides, polypeptides, and proteins. Bioconjug Chem. 2017;28(3):691\u2013700.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"1837_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ajmg.c.31319","volume":"160C","author":"DS Bali","year":"2012","unstructured":"Bali DS, et al. Predicting cross-reactive immunological material (CRIM) status in pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet. 2012;160\u00a0C(1):40\u20139.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"12","key":"1837_CR22","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/labinvest.3700484","volume":"86","author":"BL Thurberg","year":"2006","unstructured":"Thurberg BL, et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease. Lab Invest. 2006;86(12):1208\u201320.","journal-title":"Lab Invest"},{"issue":"5","key":"1837_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/01.gim.0000195896.04069.5f","volume":"8","author":"AK Ansong","year":"2006","unstructured":"Ansong AK, et al. Electrocardiographic response to enzyme replacement therapy for pompe disease. Genet Med. 2006;8(5):297\u2013301.","journal-title":"Genet Med"},{"issue":"4","key":"1837_CR24","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s10554-020-02097-9","volume":"37","author":"G Cundari","year":"2021","unstructured":"Cundari G, et al. Use of the new Lake Louise Criteria improves CMR detection of atypical forms of acute myocarditis. Int J Cardiovasc Imaging. 2021;37(4):1395\u2013404.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"5","key":"1837_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/14779072.2018.1455499","volume":"16","author":"VO Puntmann","year":"2018","unstructured":"Puntmann VO, Zeiher AM, Nagel E. T1 and T2 mapping in myocarditis: seeing beyond the horizon of Lake Louise criteria and histopathology. Expert Rev Cardiovasc Ther. 2018;16(5):319\u201330.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"1837_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1113\/expphysiol.2012.068577","volume":"98","author":"CM Moran","year":"2013","unstructured":"Moran CM, et al. High-resolution echocardiography in the assessment of cardiac physiology and disease in preclinical models. Exp Physiol. 2013;98(3):629\u201344.","journal-title":"Exp Physiol"},{"issue":"4","key":"1837_CR27","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jacc.2018.10.038","volume":"73","author":"JU Doherty","year":"2019","unstructured":"Doherty JU, et al. ACC\/AATS\/AHA\/ASE\/ASNC\/HRS\/SCAI\/SCCT\/SCMR\/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac structure and function in Nonvalvular Heart Disease: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of thoracic surgeons. J Am Coll Cardiol. 2019;73(4):488\u2013516.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1837_CR28","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/j.1460-9592.2007.02215.x","volume":"17","author":"LY Wang","year":"2007","unstructured":"Wang LY, et al. Cardiac arrhythmias following anesthesia induction in infantile-onset pompe disease: a case series. Paediatr Anaesth. 2007;17(8):738\u201348.","journal-title":"Paediatr Anaesth"},{"issue":"6","key":"1837_CR29","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1460-9592.2004.01242.x","volume":"14","author":"RJ Ing","year":"2004","unstructured":"Ing RJ, et al. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach. Paediatr Anaesth. 2004;14(6):514\u20139.","journal-title":"Paediatr Anaesth"},{"issue":"2","key":"1837_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1148\/radiology.169.2.2971985","volume":"169","author":"J Katz","year":"1988","unstructured":"Katz J, et al. Estimation of human myocardial mass with MR imaging. Radiology. 1988;169(2):495\u20138.","journal-title":"Radiology"},{"issue":"2","key":"1837_CR31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.21037\/cdt-20-948","volume":"11","author":"G Femia","year":"2021","unstructured":"Femia G, et al. Post-mortem cardiac magnetic resonance parameters in normal and diseased conditions. Cardiovasc Diagn Ther. 2021;11(2):373\u201382.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"2","key":"1837_CR32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1081\/JCMR-200053515","volume":"7","author":"B Sievers","year":"2005","unstructured":"Sievers B, et al. Impact of the ECG gating method on ventricular volumes and ejection fractions assessed by cardiovascular magnetic resonance imaging. J Cardiovasc Magn Reson. 2005;7(2):441\u20136.","journal-title":"J Cardiovasc Magn Reson"},{"key":"1837_CR33","doi-asserted-by":"crossref","unstructured":"Kamp NJ, et al. Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Prog Cardiovasc Dis; 2020.","DOI":"10.1016\/j.pcad.2020.11.001"},{"issue":"5","key":"1837_CR34","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s10554-020-02134-7","volume":"37","author":"M Joshi","year":"2021","unstructured":"Joshi M, et al. AL cardiac amyloidosis with widespread myocardial infiltration in the absence of hyperenhancement on conventional magnitude late gadolinium enhancement cardiovascular magnetic resonance imaging. Int J Cardiovasc Imaging. 2021;37(5):1709\u201310.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"5","key":"1837_CR35","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/ehf2.12830","volume":"7","author":"T Emrich","year":"2020","unstructured":"Emrich T, et al. T1 and T2 mapping to detect chronic inflammation in cardiac magnetic resonance imaging in heart failure with reduced ejection fraction. ESC Heart Fail. 2020;7(5):2544\u201352.","journal-title":"ESC Heart Fail"},{"key":"1837_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1532-429X-14-88","volume":"14","author":"M Fontana","year":"2012","unstructured":"Fontana M, et al. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn Reson. 2012;14:88.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"1837_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12880-019-0362-0","volume":"19","author":"JF Heidenreich","year":"2019","unstructured":"Heidenreich JF, et al. T1- and ECV-mapping in clinical routine at 3 T: differences between MOLLI, ShMOLLI and SASHA. BMC Med Imaging. 2019;19(1):59.","journal-title":"BMC Med Imaging"},{"key":"1837_CR38","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.ijcard.2016.07.182","volume":"222","author":"R Hinojar","year":"2016","unstructured":"Hinojar R, et al. Native T1 and T2 mapping by CMR in lupus myocarditis: Disease recognition and response to treatment. Int J Cardiol. 2016;222:717\u201326.","journal-title":"Int J Cardiol"},{"key":"1837_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1532-429X-15-92","volume":"15","author":"JC Moon","year":"2013","unstructured":"Moon JC, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"3","key":"1837_CR40","first-page":"246","volume":"48","author":"D Alis","year":"2020","unstructured":"Alis D, et al. Diagnostic values of edema-sensitive T2-weighted imaging, TSE T1-weighted early contrast-enhanced imaging, late gadolinium enhancement, and the Lake Louise criteria in assessing acute myocarditis: a single-center cardiac magnetic resonance study. Turk Kardiyol Dern Ars. 2020;48(3):246\u201354.","journal-title":"Turk Kardiyol Dern Ars"},{"issue":"13","key":"1837_CR41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.21037\/atm.2019.04.70","volume":"7","author":"A Hahn","year":"2019","unstructured":"Hahn A, Schanzer A. Long-term outcome and unmet needs in infantile-onset pompe disease. Ann Transl Med. 2019;7(13):283.","journal-title":"Ann Transl Med"},{"issue":"3","key":"1837_CR42","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1017\/S1047951121002079","volume":"32","author":"BJ Byrne","year":"2022","unstructured":"Byrne BJ, et al. Cardiac responses in paediatric pompe disease in the ADVANCE patient cohort. Cardiol Young. 2022;32(3):364\u201373.","journal-title":"Cardiol Young"},{"issue":"3","key":"1837_CR43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","volume":"66","author":"PS Kishnani","year":"2009","unstructured":"Kishnani PS, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with pompe disease. Pediatr Res. 2009;66(3):329\u201335.","journal-title":"Pediatr Res"},{"issue":"1","key":"1837_CR44","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3233\/JND-230164","volume":"11","author":"C Pfrimmer","year":"2024","unstructured":"Pfrimmer C, et al. Long-term outcome of Infantile Onset Pompe Disease patients treated with enzyme replacement therapy - data from a german-austrian cohort. J Neuromuscul Dis. 2024;11(1):167\u201377.","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"1837_CR45","first-page":"114","volume":"42","author":"T Fukuda","year":"2010","unstructured":"Fukuda T. The efficacy of enzyme replacement therapy in pompe disease and secondary pathology in pompe muscle excessive autophagy which is relevant to the therapy resistance]. No Hattatsu. 2010;42(2):114\u20136.","journal-title":"No Hattatsu"},{"issue":"1","key":"1837_CR46","first-page":"45","volume":"26","author":"N Raben","year":"2007","unstructured":"Raben N, Roberts A, Plotz PH. Role of autophagy in the pathogenesis of pompe disease. Acta Myol. 2007;26(1):45\u20138.","journal-title":"Acta Myol"},{"key":"1837_CR47","first-page":"71","volume":"21","author":"C Angelini","year":"2015","unstructured":"Angelini C, Nascimbeni AC, Fanin M. Autophagy in natural history and after ERT in glycogenosis type II. JIMD Rep. 2015;21:71\u20137.","journal-title":"JIMD Rep"},{"issue":"4","key":"1837_CR48","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4161\/auto.2984","volume":"2","author":"T Fukuda","year":"2006","unstructured":"Fukuda T, et al. Autophagy and lysosomes in pompe disease. Autophagy. 2006;2(4):318\u201320.","journal-title":"Autophagy"},{"issue":"5","key":"1837_CR49","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1086\/522236","volume":"81","author":"B Sun","year":"2007","unstructured":"Sun B, et al. Enhanced response to enzyme replacement therapy in pompe disease after the induction of immune tolerance. Am J Hum Genet. 2007;81(5):1042\u20139.","journal-title":"Am J Hum Genet"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-025-01837-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-025-01837-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-025-01837-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T06:21:48Z","timestamp":1737613308000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-025-01837-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1837"],"URL":"https:\/\/doi.org\/10.1186\/s13052-025-01837-8","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"7 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols were approved from ethical committee in Mansoura university (IRB number MD.21.01.404). Written Informed consent was obtained from the patients (if above 16) or patient\u2019s legal guardian for participation in the research. All methods were performed in accordance with the ethical standards as laid down in the Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the patient\u2019s guardian for their child\u2019s information to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Studies involving animals"}},{"value":"No conflicts of interest or financial conflict.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"13"}}